drugset / Trial / NCT03798236
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Phase 1
Completed
32 enrolled
Palobiofarma SL
Clinica Universidad de Navarra, Universidad de Navarra · collab
RandomizedSequentialDouble-blindTreatment
Summary
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
Timeline
- Start
- 2018-12-10
- Primary completion
- 2019-03-30
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PBF-1650 | Unknown | 40 mg | Oral |
| Subject | PBF-1650 | Unknown | 80 mg | Oral |
| Subject | PBF-1650 | Unknown | 120 mg | Oral |
| Subject | PBF-1650 | Unknown | 240 mg | Oral |